1 4 4 3 t e c h n i c a l r e p o r t s Haplotype phasing is a fundamental problem in medical and population genetics. Phasing is generally performed via statistical phasing in a genotyped cohort, an approach that can yield high accuracy in very large cohorts but attains lower accuracy in smaller cohorts. Here we instead explore the paradigm of reference-based phasing. We introduce a new phasing algorithm, Eagle2, that attains high accuracy across a broad range of cohort sizes by efficiently leveraging information from large external reference panels (such as the Haplotype Reference Consortium; HRC) using a new data structure based on the positional Burrows-Wheeler transform. We demonstrate that Eagle2 attains a 20× speedup and ~10% increase in accuracy compared to reference-based phasing using SHAPEIT2. On Europeanancestry samples, Eagle2 with the HRC panel achieves >2× the accuracy of 1000 Genomes-based phasing. Eagle2 is open source and freely available for HRC-based phasing via the Sanger Imputation Service and the Michigan Imputation Server.
Haplotype phasing is a central problem in human genetics 1 . Over the past decade, phasing has most commonly been performed via statistical methods applied in a genotyped cohort [2] [3] [4] [5] [6] [7] [8] [9] [10] [11] [12] [13] [14] . Wet-lab technologies for direct phasing have also generated considerable recent interest, but these methods are currently much less scalable 15 . In general, the accuracy of statistical phasing methods increases steadily with sample size owing to improved modeling of linkage disequilibrium and increasing prevalence of identity by descent. We and others have recently developed methods that achieve very high statistical phasing accuracy in cohorts comprising a large fraction of a population 8 or containing >100,000 samples 13, 14 . However, for smaller cohorts, accuracy of cohort-based statistical phasing is fundamentally limited by the quantity of data available.
Here we explore an alternative paradigm, reference-based phasing, which can be used to achieve high accuracy even in smaller cohorts by leveraging information from an external reference panel. This paradigm targets a user group complementary to recent methods for phasing very large cohorts 13, 14 . In particular, methods for mapping molecular QTLs using allele-specific reads require accurate phasing information, but recent papers introducing these methods have reported that inaccurate phasing currently limits their potential 16, 17 .
We present a new reference-based phasing algorithm, Eagle2, which we incorporated into the Sanger Imputation Service and the Michigan Imputation Server 18 to perform free reference phasing using the 32,470sample HRC panel 19 . This approach achieved >2× improved phasing accuracy over 1000 Genomes-based phasing on small Europeanancestry cohorts, with smaller improvements for larger cohort sizes. The Eagle2 algorithm represents a substantial computational advance over existing reference-based phasing algorithms: Eagle2 achieved a 20× speedup over SHAPEIT2 (ref. 12) , i.e., genome-wide phasing in 1.5 min per sample, with a 10% improvement in accuracy across a range of ancestries. Eagle2 achieved this performance via two key ideas that distinguish it from previous phasing algorithms 3-14 : a new data structure based on the positional Burrows-Wheeler transform 20 and a rapid search algorithm that explores only the most relevant phase paths through a hidden Markov model (HMM). We released Eagle2 as open-source software (see URLs).
RESULTS

Overview of methods
The Eagle2 phasing algorithm takes as input a diploid target sample and a library of reference haplotypes. The statistical model underlying Eagle2 is a haplotype copying model similar to the Li-Stephens model 21 used by previous HMM-based methods. However, Eagle2 has two key differences compared to previous HMM-based methods. t e c h n i c a l r e p o r t s First, whereas previous approaches approximate the haplotype structure (for example, by merging haplotypes into local clusters) to produce a more tractable HMM, Eagle2 efficiently represents the full haplotype structure in a way that losslessly condenses locally matching haplotypes. Second, using this representation, Eagle2 selectively explores the space of diplotypes (i.e., complementary pairs of phased haplotypes) in a way that only expends computation on the most likely phase paths (i.e., diplotypes with highest posterior probabilities). This approach is distinct from the dynamic programming or sampling methods used in previous phasing software and enables much greater computational efficiency. In more detail, Eagle2 efficiently represents haplotype structure by introducing a new data structure, the HapHedge, which can be generated in linear time using the positional Burrows-Wheeler transform 20 . Eagle2 then explores diplotypes using a branching-and-pruning beam search. We provide a schematic of the method in Figure 1 , and present full details in Online Methods and Supplementary Note.
We note that the Eagle2 algorithm is very different from the longrange phasing algorithm we recently developed for phasing extremely large cohorts 13 . (We refer to the previous method as Eagle1.) The basic idea of Eagle1 was to harness identity by descent among distant relatives, which is pervasive at very large sample sizes but rare among smaller numbers of samples, to rapidly call phase using a fast scoring approach. In contrast, Eagle2 analyzes a full probabilistic model similar to the diploid Li-Stephens model used by previous HMM-based methods. Consequently, whereas Eagle1 had decreased accuracy compared to HMM-based methods when used to phase <50,000 samples, Eagle2 achieves improved accuracy over previous methods for both small and large haplotype reference panel sizes, as we demonstrate below. We note that when a reference panel contains fewer than twice as many samples as the target cohort, Eagle2 iteratively augments the reference panel with inferred target haplotypes (Online Methods); under this paradigm, reference-based phasing should always improve accuracy over cohort-based phasing. We also note that the Eagle1 algorithm was originally only implemented for cohort-based phasing; in this work, we extended the implementation to reference-based phasing for the sake of comparison. Likewise, we implemented a cohort-based version of Eagle2 that we also benchmark below.
Phasing performance using genotyped reference panels
We first benchmarked Eagle2 against previous reference-based phasing methods using reference panels generated by phasing subsets of genotyped cohorts. These benchmarks allowed us to explore a greater range of reference panel sizes and genetic ancestries than currently available in sequenced reference panels (as the N = 32,470 samples currently in the HRC are predominantly European), understanding that genotyped reference panels containing a limited set of markers are not broadly useful for reference-based phasing. We performed benchmarks using a total of five data sets: the UK Biobank cohort 22 and the four GERA sub-cohorts, which were genotyped on four distinct European, African, East Asian, and Latino genotyping arrays 23, 24 . All five data sets were previously genotyped on arrays containing 650,000-850,000 autosomal markers with typical heterozygosity and missingness rates, and each data set contained a small subset of mother-father-child trios (Online Methods and Supplementary Table 1 ).
For the UK Biobank reference-based phasing benchmarks, we generated simulated reference panels by randomly selecting N ref = 15,000, 30,000, 50,000 or 100,000 samples (not containing trio members) and phasing them using Eagle1 (ref. 13) . We phased each subset independently (rather than phasing all samples together and then extracting subsets) to better reflect the phase inaccuracy that would be present in a real reference panel of a given size. We then benchmarked the computational cost and accuracy of reference-based phasing methods by using each panel of 2N ref haplotypes to phase sets of other UK Biobank target samples including the 70 European-ancestry trio children, which we used for benchmarking accuracy (Online Methods). To cover a wide range of linkage disequilibrium structure, we performed these benchmarks on chromosomes 1, 5, 10, 15 and 20 (a total of 174,595 markers comprising ~25% of the genome) using Eagle2, SHAPEIT2 (ref. 12) , SHAPEIT2 with its -no-mcmc option (which increases speed at the expense of accuracy) and a referencebased version of Eagle1 that we implemented for comparison. We also attempted to benchmark Beagle v4.1 (ref. 25) but found it was too slow for this benchmark to be practical: for the smallest analysis (chromosome 20 with N ref = 15,000 and N target = 72), Beagle v4.1 required 3.6 d (in contrast to 1.1 min for Eagle2). (We note that the focus of Beagle v4.1 is its haploid imputation algorithm, which is much faster than its phasing algorithm.) We did not benchmark HAPI-UR 11 as HAPI-UR does not implement reference-based phasing.
We observed that Eagle2 achieved 12-38× speedups over SHAPEIT2 for performing reference-based phasing using panels of size N ref = 15,000-100,000 ( Fig. 2a, and Supplementary Tables 2 and 3) . Moreover, unlike the other methods we benchmarked, the computation time Eagle2 required to phase each target sample was nearly independent of the reference size. (For very large reference panels with N ref >> 100,000, the computational cost of Eagle2 will eventually increase with N ref ; see Online Methods and Supplementary Note.) Eagle2 achieved running times similar to Eagle1 and ~2× faster than SHAPEIT2 -no-mcmc (both of which are much less accurate methods than Eagle2 and SHAPEIT2 when used with reference panels of such sizes; see below). All methods had low memory costs (<7 GB for M = 57,753 SNPs on chromosome 1 with N ref = 100,000; Supplementary Table 3 ).
In our accuracy benchmarks, which we computed using goldstandard trio phase calls, we observed that Eagle2 achieved 5-16% lower switch error rates 2 compared to SHAPEIT2, with larger gains Figure 1 Schematic of the Eagle2 core phasing algorithm. (a) Given diploid genotypes from a target sample along with a haploid reference set of conditioning haplotypes, our algorithm proceeds in two steps. We use the positional Burrows-Wheeler transform (PBWT) 20 to generate a 'hedge' of haplotype prefix trees rooted at markers spaced across the chromosome. These trees encode haplotype prefix frequencies, represented here by branch thicknesses. (b) We explore a small set of high-probability diplotypes (i.e., complementary pairs of phased haplotypes), estimating diplotype probabilities under a haplotype-copying model by summing over possible recombination points. For each possible choice of recombination points, the HapHedge data structure allows rapid lookup of haplotype segment frequencies. This illustration is meant to provide intuition for the overall approach; our optimized software implementation first 'condenses' reference haplotypes based on the target genotypes. Details are provided in supplementary Figure 1 and the supplementary note. t e c h n i c a l r e p o r t s for lower values of N ref in the 15,000-100,000 range ( Fig. 2b and Supplementary Table 2 ). Eagle2 achieved 4-36% lower switch error rates than Eagle1 and 63-81% lower switch error rates than SHAPEIT2 -no-mcmc in the same N ref range. All differences were significant (binomial P ≤ 0.003 for each comparison of Eagle2 with SHAPEIT2, P ≤ 0.02 for each comparison with Eagle1, and P = 10 −21 for each comparison with SHAPEIT2 -no-mcmc). Both Eagle2 and SHAPEIT2 have an important parameter, K, which specifies the number of conditioning haplotypes used to phase each target sample and thus adjusts the speed-accuracy tradeoff. We therefore also investigated the effects of varying K. (We note that the default values and precise meaning of this parameter are different for Eagle2 vs. SHAPEIT2; by default, SHAPEIT2 locally selects K = 100 best reference haplotypes in each 2-Mb window, wheras Eagle2 selects a fixed set of K = 10,000 best reference haplotypes to use for the entire chromosome. This difference may be responsible for the slightly lower rate of improvement in accuracy of Eagle2 relative to that of SHAPEIT2 as N ref increases at fixed K in Fig. 2b.) We considered a range of values of K from 0.5-4 times the default K, similar to previous benchmarks of SHAPEIT2 (ref. 12 ). The effects of varying K were broadly consistent for Eagle2, SHAPEIT2, and SHAPEIT2 -no-mcmc: all methods required similarly increased computation time and achieved improved accuracy with larger values of K ( Fig. 2c,d, and Supplementary Tables 2 and 3) .
In particular, increasing the number of conditioning haplotypes by a factor of 4x required 2-3× more computation time for both Eagle2 and SHAPEIT2 while achieving similar decreases in switch error rates (12-20% and 17-19%, respectively, for N ref = 15,000-100,000; Supplementary Table 2 ). All improvements were statistically significant (binomial P = 10 −8 or less).
To assess the robustness of these accuracy benchmarks across genetic ancestries, we performed a similar set of benchmarks using the European, African, East Asian, and Latino GERA sub-cohorts (Online Methods). Because the latter three sub-cohorts were relatively small ( Supplementary Table 1 ), we generated a single simulated reference panel for each sub-cohort containing all samples not belonging to trio pedigrees (N ref = 3,817, 5,164, 7,144, and 61,684 for the African, East Asian, Latino, and European sub-cohorts). We phased the three smaller panels using SHAPEIT2 and phased the European panel using Eagle1. We then benchmarked reference-based phasing accuracy by phasing the trio parents within each sub-cohort using the panel generated from that sub-cohort, running each method with default parameter settings. (We phased trio parents rather than trio children for these benchmarks because the three smaller data sets contained only 3-7 independent trios each; Supplementary Table 1 .) These benchmarks confirmed our findings from the UK Biobank data: Eagle2 achieved 5-23% lower switch error rates than SHAPEIT2, and we observed the same relative ordering of accuracies as before across all sub-cohorts ( Fig. 3 and Supplementary Table 4 ). All differences were statistically significant (binomial P = 10 −7 or less). We note that every method had a higher switch error rate with the GERA European sub-cohort compared to the error rate with the UK Biobank data, presumably primarily owing to a more diverse set of ancestries represented. In general, absolute switch error rates are not directly comparable among data sets because of differences in demography and genotyping properties (for example, chip density, allele frequency distribution and genotype error rate).
Phasing accuracy using the 1000 Genomes and HRC panels
We next benchmarked reference-based phasing using either the 1000 Genomes Project Phase 3 reference panel (containing N = 2,504 samples from 26 populations) 26 or the HRC reference panel r1.1 (containing N = 32,470 samples mostly of European ancestry) 19 . For these benchmarks, we used 1000 Genomes trio children as target samples, removing all 1000 Genomes trios from each reference panel before running the analyses. We phased chromosome 1, and to emulate typical genotyping density, we restricted the SNP set to 31,853 sites typed on 23andMe (customized Illumina) chips. Given the predominantly European composition of the HRC panel, the benchmarks on 32 CEU trio children were of primary interest, and we observed in these benchmarks that all methods achieved substantially improved accuracy using the HRC panel versus the 1000 Genomes panel ( Fig. 4 and Supplementary Table 5 ). For each choice of reference panel, Eagle2 achieved the lowest switch error rate, consistent with our previous results. For phasing small European cohorts, Eagle2 with the HRC panel provided a >2× improvement in accuracy over 1000 Genomes data-based phasing: 1.36% (s.e.m., 0.04%) switch error rate versus 3.52% (0.06%) using SHAPEIT2 or 3.27% (0.06%) using Eagle2 with the 1000 Genomes reference ( Fig. 4 and Supplementary Table 5 ).
We also benchmarked accuracy in all other 1000 Genomes populations containing >1 trio. We phased trio children in 31 Han Chinese (CHS) trios, 30 Peruvian (PEL) trios, 15 Punjabi (PJL) trios, and 19 Yoruba (YRI) trios using either the 1000 Genomes panel or the HRC panel, and we observed that in all cases Eagle2's accuracy was either slightly better or statistically indistiguishable from SHAPEIT2's ( Supplementary Table 5 ). Specifically, the differences between Eagle2 and SHAPEIT2 were not significant for PEL with either reference panel and for YRI with HRC (P = 0.05 or larger); all other differences were significant (binomial P ≤ 0.006). All methods achieved slightly lower accuracy using the HRC panel versus the 1000 Genomes panel (Supplementary Table 5 ). Given that the HRC panel contains the 1000 Genomes panel, this observation suggests that the inclusion of ~30,000 additional predominantly European samples reduced the ability of each method to model the haplotype structure of non-European populations. However, we did not observe this phenomenon when phasing the two non-European UK Biobank trios using increasing numbers of European reference haplotypes ( Supplementary Table 6 ), so this observation may be specific to the current HRC release (r1.1); development of the HRC is ongoing.
Phasing performance without a reference panel
Lastly, we assessed the performance of Eagle2 when applied to cohortbased phasing, which we also implemented in our software. The Eagle2 cohort-based phasing algorithm starts by running the first two steps of Eagle1 (ref. 13) to rapidly produce rough haplotype estimates and then refines these estimates using the Eagle2 core phasing algorithm (Online Methods). We benchmarked Eagle2, Eagle1 and SHAPEIT2 on subsets of the UK Biobank data set containing N = 5,000, 15,000, 50,000 or 150,000 samples (including trio children and excluding trio parents). We phased chromosomes 1, 5, 10, 15 and 20 as in our UK Biobank reference-based phasing benchmarks, and we allowed each computational job up to 5 d to complete. We observed that Eagle2 exhibited computational efficiency similar to Eagle1, achieving 5-6× speedups over SHAPEIT2 in the analyses SHAPEIT2 completed (N = 5,000 and N = 15,000) ( Fig. 5a, and Supplementary Tables 7  and 8) . Eagle2 also exhibited close to linear run-time scaling across this sample size range, breaking even with Eagle1 at N = ~30,000 and achieving faster running times for larger N values. Figure 4 Accuracy of reference-based phasing using the 1000 Genomes and HRC panels. We phased 32 trio children from the 1000 Genomes CEU population using either the 1000 Genomes t e c h n i c a l r e p o r t s
In our accuracy benchmarks using the 70 European-ancestry UK Biobank trios, we observed that Eagle2 achieved better accuracy than SHAPEIT2 and Eagle1 for N ≤ 50,000, as expected ( Fig. 5b, and  Supplementary Tables 7 and 8) . At N = 150,000, Eagle1 achieved a slightly lower switch error rate (0.31%; s.e.m., 0.02%) than Eagle2 (0.35%; s.e.m., 0.02%). However, we observed that running Eagle2 with 4× the default number of conditioning haplotypes (i.e., K = 40,000) achieved the lowest error rates across all sample sizes tested (0.27%, s.e.m., 0.02% at N = 150,000). Both differences were statistically significant (binomial P ≤ 0.0006). Finally, we confirmed that Eagle2 achieved better phasing accuracy than SHAPEIT2 or Eagle1 when used to phase the GERA samples in each GERA sub-cohort (Supplementary Table 9) , with switch error rates consistent with our earlier reference-based benchmarks ( Fig. 3 and Supplementary  Table 4 ). All differences were significant (binomial P ≤ 0.002).
DISCUSSION
We described a new phasing algorithm, Eagle2, which we incorporated into the Sanger Imputation Service and the Michigan Imputation Server to offer free reference-based phasing using the 32,470-sample Haplotype Reference Consortium panel. This service enables highaccuracy phasing even in smaller cohorts, which was not previously possible. Eagle2 achieves substantial gains in speed and accuracy over previous methods via a new search-based algorithm using the positional Burrows-Wheeler transform. We believe this method is timely, as large sequenced reference panels (for example, the HRC data) are now becoming available for use, but must be used via analyses run on central servers due to consent restrictions. We anticipate that Eagle2's phasing speed of 1.5 min per genotyped sample will help keep computation tractable as demand for this service increases. Additionally, we anticipate that our release of Eagle2 as open-source software will aid future method development and integration into analysis pipelines.
We note that Eagle2 targets a distinct user group compared to very recent work on phasing very large cohorts 13, 14 . In particular, our Eagle1 method 13 is targeted at phasing very large (N > 100,000) cohorts and achieves much lower accuracy than both Eagle2 and previous methods when used to phase smaller cohorts. The SHAPEIT3 method 14 is likewise targeted at phasing 'biobank-scale datasets' . The information provided in the paper describing SHAPEIT3 (ref. 14) indicates that its primary advance is removing a quadratic complexity component of the SHAPEIT2 algorithm that becomes significant as N increases beyond 10,000 samples; this computational speedup comes at the expense of reduced accuracy. The benchmarks in ref. 14 suggest that if used to perform HRC-based phasing at N ref = 32,470, SHAPEIT3 would be ~3× faster but roughly 20% less accurate than SHAPEIT2; in contrast, Eagle2 is ~20× faster and ~10% more accurate than SHAPEIT2 at this sample size. (In practice, the SHAPEIT license precludes its use for reference-based phasing on the Sanger and Michigan HRC servers.)
Athough we believe that reference-based phasing using large reference panels such as the HRC is a valuable phasing paradigm, we note a few limitations. First, reference-based phasing accuracy is limited not only by reference panel size but also by genotyping and phasing accuracy in the reference panel. In particular, the HRC reference haplotypes are largely derived from low-coverage sequencing data (which is generally prone to higher errors in genotype calling), and efforts to improve the accuracy of the reference panel are ongoing. Second, for reference-based phasing to be effective, the reference panel needs to contain a sizable subset of samples with genetic ancestry well matched to the target samples. As a consequence, phasing using the HRC data is currently only advantageous for European-ancestry target samples, although plans are underway to grow the HRC dataset to better represent worldwide populations. Third, for very large cohorts (substantially larger than the reference size), we expect that referencebased phasing will achieve only marginal gains in accuracy over cohort-based phasing. For such cohorts, we expect that cohort-based phasing may remain the preferred option due to ease of execution, although reference sizes are growing, and if the end goal is imputation based on HRC data, then we expect that HRC data-based pre-phasing 27 will be more convenient. Finally, we did not fully optimize Eagle2 for phasing sequenced samples 28, 29 . Although a preliminary benchmark against SHAPEIT2 suggests that Eagle2 achieves gains in speed and accuracy on sequence data comparable to its improvements on genotype data (Supplementary Table 10) , more investigation will be needed to tune the method and benchmark it against other approaches (for example, the recent SHAPEITR method 30 , which is available via the Oxford Statistics Phasing Server; see URLs). Despite these limitations, we expect that reference-based phasing using Eagle2 and the HRC panel will be a valuable resource providing free, fast and accurate phasing to the scientific community. 
URLs
METHODS
Methods and any associated references are available in the online version of the paper.
Note: Any Supplementary Information and Source Data files are available in the online version of the paper.
Evaluation of reference-based phasing using genotyped reference panels. For our reference-based phasing benchmarks using genotyped UK Biobank data, we constructed reference panels by randomly selecting N ref = 15,000, 30,000, 50,000 or 100,000 samples (disjoint from the 72 UK Biobank trios) and phasing these samples using Eagle1 (as phasing using SHAPEIT2 would have required several weeks 13 ). We then applied each reference-based phasing method to phase chromosomes 1, 5, 10, 15 and 20 of the N target = 72 trio children using each simulated reference panel, and we compared the phased output against trio phase calls to compute switch error rates 2, 13 . In our results, we report mean switch error rates and s.e.m. over the 70 European-ancestry trio children (according to self-reported ethnicity; see above).
To benchmark per-sample computational cost of reference-based phasing, we performed an additional set of analyses in which we phased 1,000 randomly selected samples (not contained in the simulated reference panels) in addition to the 72 trio children. We subtracted the N target = 72 running times from the N target = 1,072 running times to obtain the incremental cost of phasing 1,000 samples, thus adjusting for initialization costs (for example, reading the reference data and synchronizing it with the target data), which account for a non-neglibible fraction of total computational cost when N target is small. Finally, we divided by 1,000 to obtain per-sample costs and multiplied by 4 to scale up from the five chromosomes analyzed (~25% of the genome) to a genome-wide analysis.
For our reference-based phasing benchmarks using GERA data, we applied an analogous procedure with the following minor differences. For each of the four sub-cohorts, we created a single simulated reference panel using all samples not in the same extended pedigree as any trio. We phased the European chip panel using Eagle1 and phased the other three panels using SHAPEIT2 (which is computationally tractable and more accurate than Eagle1 for small cohorts 13 ). In each sub-cohort, we then applied each reference-based phasing method to phase all 22 autosomes of the trio parents in that sub-cohort, and we computed mean switch error rates over all trio parents. We benchmarked accuracy using trio parents rather than trio children due to the small numbers of trios in the non-European sub-cohorts. (For the European sub-cohort, we also computed benchmarks using trio children for comparison.) For the European sub-cohort, we computed s.e.m. over samples as before; for the other three sub-cohorts, we computed s.e.m. over 25 SNP blocks because of the small numbers of trios. When used to compare methods, these standard errors are conservative due to true variation among samples and across the genome (which causes errors to be correlated). We therefore assessed statistical significance of differences in performance between pairs of methods by performing one-sided binomial tests across samples or SNP blocks as appropriate.
Evaluation of cohort-based phasing performance. For our benchmarks of phasing without a reference, we created subsets of UK Biobank samples containing N = 5,000, 15,000, 50,000 or 150,000 samples, each of which contained all 72 trio children and none of the 144 trio parents. We then applied each phasing method to phase chromosomes 1, 5, 10, 15 and 20 of each subset of samples, and we computed mean switch error rates and s.e.m. over the 70 European-ancestry trio children as above. We applied an analogous procedure to the GERA sub-cohorts with the same modifications as above. 
